Commit 6862db23 authored by 吕祺's avatar 吕祺 ⛹🏽

自动文章合并|自动图片压缩

parent 7b5b0b35
--- ---
news: news:
- title: 祝贺巨子生物港交所主板成功上市 - title: 祝贺巨子生物港交所主板成功上市
titleEN: Congratulations to Giant Biogene Listed on the HKEX
hide: false hide: false
type: 新消费 type: 新消费
typeEN: New Consumption
createDate: 2022-11-03T16:33:03.741Z createDate: 2022-11-03T16:33:03.741Z
abstract: >- abstract: >-
北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。 北京时间11月4日,中国基于生物活性成分的专业皮肤护理产品行业的领军者巨子生物(股票代码:02367.HK)在港交所主板上市,成为“胶原蛋白第一股”。此前,2021年10月,巨子生物完成了自成立以来唯一一轮融资,高榕资本参与投资。
...@@ -26,6 +28,49 @@ news: ...@@ -26,6 +28,49 @@ news:
科技和创新是巨子生物的支点,也是撬动企业指数增长的杠杆。高榕资本合伙人韩锐表示,“巨子生物完全称得上是一家十年磨一剑的公司,公司在产品研发上的投入和创新能力让人惊叹。未来,相信在范教授的科研能力和严总的企业家精神带领下,巨子会持续创造独特的价值。” 科技和创新是巨子生物的支点,也是撬动企业指数增长的杠杆。高榕资本合伙人韩锐表示,“巨子生物完全称得上是一家十年磨一剑的公司,公司在产品研发上的投入和创新能力让人惊叹。未来,相信在范教授的科研能力和严总的企业家精神带领下,巨子会持续创造独特的价值。”
contentEN: >-
On November 4, Giant Biogene (stock code: 02367.HK), a leader in China's
professional skin care product industry based on bioactive ingredients, was
listed on the main board of the HKEX, becoming the "first collagen stock".
Previously, in October 2021, Giant Biogene completed the only round of
financing since its establishment, and Gaorong Capital participated in the
investment.
![](/static/img/juziipo_22-11.jpg)
Giant Biogene is the pioneer and leader of China's recombinant collagen
industry. Dr. Fan Daidi, the core of the R&D team, is one of the leaders in
the collagen industry and even in the field of biomedical materials in
China. After years of accumulation, Giant Biogene has established a
synthetic biology technology platform integrating interdisciplinary
scientific research in biotechnology, biochemistry and bioengineering and
years of industry expertise. Giant Biogene has successively developed 33
different types of recombinant collagen and successfully mass-produced them.
In addition, it has independently developed and produced rare ginsenosides.
Before listing, Giant Biogene's professional skin care products and health
food portfolio included 106 SKUs of eight major brands, including Giant
Biogene's two flagship brands, Kefumei and Collgene. Collgene and Kefumei
are the third and fourth best-selling brands (in terms of retail sales) in
China's professional skin care product industry in 2021, respectively.
In 2021, the market size of China's functional skin care products will reach
30.8 billion yuan. Giant Biogene is the second largest professional skin
care product company in China in 2021. At the same time, it has been the
largest collagen professional skin care product company in China for three
consecutive years since 2019 .
While focusing on R&D and product capabilities, Giant Biogene has maintained
high-quality performance growth. The data shows that from 2019 to 2021, the
company's revenue is RMB 957 million, RMB 1.190 billion and RMB 1.552
billion respectively, with a compound annual growth rate of about 27.39%;
Profit reached RMB 723 million and RMB 314 million respectively, showing
strong profitability.
pic: /static/img/juziipo_22-11.jpg pic: /static/img/juziipo_22-11.jpg
highLight: true highLight: true
- title: 必示科技完成近两亿元C轮融资,推出新一代智能运维产品矩阵 - title: 必示科技完成近两亿元C轮融资,推出新一代智能运维产品矩阵
Markdown is supported
0% or
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment